Danaher Co. (NYSE:DHR) Director Linda P. Hefner sold 2,754 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $197.00, for a total value of $542,538.00. Following the completion of the transaction, the director now directly owns 32,749 shares of the company’s stock, valued at approximately $6,451,553. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
NYSE DHR opened at $202.14 on Friday. The firm has a market cap of $141.34 billion, a PE ratio of 43.28, a price-to-earnings-growth ratio of 3.19 and a beta of 0.92. Danaher Co. has a one year low of $119.60 and a one year high of $204.13. The stock’s 50 day simple moving average is $181.65 and its 200 day simple moving average is $161.73. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.20 and a quick ratio of 1.74.
Danaher (NYSE:DHR) last released its quarterly earnings results on Thursday, July 23rd. The conglomerate reported $1.44 EPS for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.35. The business had revenue of $5.30 billion for the quarter, compared to analyst estimates of $5.01 billion. Danaher had a return on equity of 11.88% and a net margin of 17.73%. Danaher’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.09 EPS. As a group, equities analysts expect that Danaher Co. will post 5.36 earnings per share for the current year.
Several research firms have commented on DHR. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $195.00 price target for the company in a report on Tuesday, June 16th. Robert W. Baird increased their target price on Danaher from $163.00 to $205.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Citigroup increased their target price on Danaher from $180.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, May 8th. UBS Group increased their target price on Danaher from $176.00 to $233.00 and gave the stock a “buy” rating in a report on Monday. Finally, Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $203.00 target price for the company in a report on Tuesday, July 21st. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Danaher presently has a consensus rating of “Buy” and an average price target of $197.73.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bainco International Investors boosted its position in Danaher by 1.7% in the 2nd quarter. Bainco International Investors now owns 47,188 shares of the conglomerate’s stock valued at $8,344,000 after buying an additional 770 shares during the last quarter. Park Avenue Securities LLC bought a new position in Danaher in the 2nd quarter valued at $3,686,000. FARMERS & MERCHANTS TRUST Co OF LONG BEACH boosted its position in Danaher by 0.6% in the 2nd quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 8,929 shares of the conglomerate’s stock valued at $1,579,000 after buying an additional 54 shares during the last quarter. Signaturefd LLC boosted its position in Danaher by 6.6% in the 2nd quarter. Signaturefd LLC now owns 9,752 shares of the conglomerate’s stock valued at $1,724,000 after buying an additional 601 shares during the last quarter. Finally, Brinker Capital Inc. boosted its position in Danaher by 18.0% in the 2nd quarter. Brinker Capital Inc. now owns 94,676 shares of the conglomerate’s stock valued at $16,745,000 after buying an additional 14,430 shares during the last quarter. Hedge funds and other institutional investors own 77.67% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.